**Technology Advisory Committee B Interests Register**

**Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]**

**Publication Date: 24/02/2021**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Name | Role with NICE | Type of interest | Description of interest | Interestarose | Interestdeclared | Interest ceased | Comments |
| Mr Peter Wheatley Price | TA Committee B Member | Direct – financial  | Mr Wheatley Price’s employer, Takeda, sell two products listed as potential comparators: 1. azilsartan medoxomil potassium (brand name EDARBI). Licenced indication: "Edarbi is indicated for the treatment of essential hypertension in adults". This is in a generised market place and Takeda have no promotional effort or do deals on it. Sales were a total of £55,462 in past year.2. candesartan cilexetil (Brand name AMIAS). Licence indication includes: "Treatment of adult patients with heart failure and impaired left ventricular systolic function". This is a generised market but Takeda have had commerical deals in place with Boots and other chains to "brand equalise". Sales per month are now only £20,000 but sales for the last 12 months are £1,329,388. | NA | 20/10/2020 | NA | It was agreed that this declaration did not present a conflict of interest as these drugs (being angiotensin receptor blockers) reflect standard care and dapagliflozin is in addition to standard care. Mr Wheatley Price participated in this section of the meeting.  |
| Dr Rhiannon Owen | TA Committee B Member | Direct – financial  | Acted as a paid consultant for Daiichi Sankyo offering statistical advice on a network meta-analysis of direct acting oral-anticoagulants for the prevention of stroke in atrial fibrillation.  | NA | 29/10/2020 | NA | It was agreed that this declaration would not prevent Dr Owen from participating in this section of the meeting.  |
| Dr Klaus Witte | Clinical Expert  | Direct - financial | Provided consulting advice to AstraZeneca on how and when the agent would be used in primary and secondary care during meetings at conferences and advisory boards. Participated in one advisory board (20th Jan 2020) to discuss how dapagliflozin would fit into the existing pathway for the management of heart failure | NA | 14/04/2020 | NA | It was agreed that this declaration would not prevent Dr Witte from providing expert advice to the committee. |
| Dr Klaus Witte | Clinical Expert  | Direct - financial | Out of hours generic primary care discussions on the optimal management of diabetes (not heart failure) for which he received an honorarium in September 2019, November 2019, January 2020 and February 2020.Paid involvement in other non-promotional educational meetings including: 1st Sept 2019 (European Society of Cardiology invited talk) – Sacubatril/valsartan (supported by Novartis)1st Sept 2019 (European Society of Cardiology invited talk) - Rivaroxaban (supported by Bayer)4th March 2020 – diabetes management (Pfizer/BMS)Participated in educational activities; a primary school education video and classroom teaching in October and November 2019. The activities were paid for by Bayer.  | NA | 12/11/2020 | NA | It was agreed that these declarations would not prevent Dr Witte from providing expert advice to the committee. |
| Mr Nick Hartshorne-Evans | Patient Expert | Direct non-financial interest | Speaker at a ‘hackathon’ - the monies received went to the Pumping Marvellous charity and not Nick himself. | NA |  | NA | It was agreed that this declaration did not prevent Mr Hartshorne-Evans from providing expert advice to the committee. |